We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY - Free Report) reported fourth-quarter 2019 earnings of 74 cents per American depositary share, which beat the Zacks Consensus Estimate of 70 cents. Earnings increased 21.8% on a reported basis. At constant currency rates (CER), earnings rose 17.3% driven by higher revenues and lower costs.
Fourth-quarter net sales of the French pharma giant rose 6.8% on a reported basis to $10.66 billion (€9.6 billion). Exchange rate movements benefited sales by 2.1% driven by a strong dollar and Japanese yen. At CER, sales increased 4.7% year over year. Sales however missed the Zacks Consensus Estimate of $11.12 billion.
Sales rose 11.8% at CER in the United States and 1.8% in the Emerging Markets. Sales were flat in Europe at CER but rose 0.6% in the Rest of the World (Japan, South Korea, Canada, Australia, New Zealand and Puerto Rico).
All growth rates mentioned below are on a year-on-year basis and at CER.
Segmental Performance
Sanofi reports through five Global Business Units (GBUs) — Sanofi Genzyme (Specialty Care), Primary Care, China & Emerging Markets, Consumer Healthcare and Vaccines.
At its Capital Markets Day held in December 2019, Sanofi announced plans to restructure the company‘s operations under three GBUs – Specialty Care (immunology, rare diseases, rare blood disorders, neurology and oncology), Vaccines and General Medicines (diabetes, cardiovascular, and established products). The company’s Consumer Healthcare (CHC) will operate as a standalone business unit.
Pharmaceuticals sales (including the emerging markets) rose 2.4% in the fourth quarter to €6.55 billion driven by key eczema drug, Dupixent, which was partially offset by lower Diabetes and Established Rx products sales.
Sanofi Genzyme/Specialty Care GBU sales (excluding the emerging markets) increased 19.7% to €2.53 billion, driven by Dupixent.
In the immunology franchise, Dupixent generated sales of €668 million in the quarter, up 133.1%. Sales of the drug in the United States were €545 million, up 134.7% driven by continued growth in atopic dermatitis and rapid uptake in new asthma indication and launch in chronic rhinosinusitis with nasal polyposis in June 2019. Sales in Europe were €64 million, up 117.2%.
Kevzara recorded sales of €53 million in the quarter, up 64.5%. Sanofi markets Dupixent and Kevzara in partnership with Regeneron Pharmaceuticals (REGN - Free Report) .
Sales of rare disease drugs increased 0.8% to €661 million. Myozyme/Lumizyme rose 2.1% to €197 million, Fabrazyme sales were €186 million, up 0.6%. Cerezyme sales declined 6.3% to €121 million.
Oncology sales increased 12.6% to €333 million. Key cancer drug Jevtana’s sales were up 10.1% to €123 million supported by higher sales in the United States.
Sales of multiple sclerosis drugs declined 3.8% to €517 million. Aubagio sales increased 3.9% to €465 million while sales of Lemtrada fell 42.5% to €52 million.
Rare blood disorders franchise, added to Sanofi’s portfolio with the acquisition of Bioverativ in 2018, fetched sales of €293 million, down 2.4% year over year. New drug Cablivi (caplacizumab) generated sales of €16 million in the quarter, lower than €20 million in the previous quarter, primarily due to price adjustments in Europe and increased assistance program participation in the United States. Sales of another drug in the franchise, Eloctate declined 14.9% in the quarter due to the ongoing competitive pressure in the United States.
Primary Care GBU comprises the Diabetes and Cardiovascular and the Established Rx Products segments. Sales in the Primary Care GBU declined 8.7% to €2.33 billion hurt by lower sales in Diabetes and Established Products.
The Diabetes franchise (excluding the emerging markets) declined 15.5% to €861 million due to lower sales of key drugs — Lantus and Toujeo.
Sales of diabetes drugs in the United States declined 20.5% to €454 million due to pricing pressure and loss of Part D business. In Europe, it dropped 4.4% and in rest of the world, it declined 21.8%.
Lantus sales decreased 23.9% to €485 million in the quarter. Lantus sales plunged 26.9% in the United States due to lower average net price and change in coverage with respect to Sanofi’s Part D business. In Europe, sales decreased 13.1% due to biosimilar competition and patient switching to Toujeo.
Toujeo generated sales of €186 million in the reported quarter, up 1.7%. Sales rose 14.3% in Europe while it declined 7.4% in the United States.
Admelog, a rapid-acting insulin, similar to Lilly’s (LLY - Free Report) Humalog, achieved sales worth €56, down 1.8% year over year.
In the cardiovascular franchise, Sanofi’s anti PCSK9 therapy, Praluent, garnered worldwide sales of €68 million in the reported quarter, down 14.1%. Sales in the United States declined due to significantly higher rebates offered by Sanofi and partner Regeneron to payers to improve access to the drug. Amgen (AMGN - Free Report) is also facing similar issues with its PCSK9 inhibitor, Repatha. Sales of the other drug, Multaq, in this franchise rose 1.1% to €97 million.
Sales of Established Rx Products came in at €1.3 billion, down 4% mainly due to lower sales of Plavix and Aprovel in China due to anticipated price and inventory adjustments in the channel. Meanwhile, lower sales of Lovenox in Europe and generic competition for Renvela/Renagel in the United Sales also hurt segment sales.
China and Emerging Markets GBU declined 1.9% to €1.7 billion.
Consumer Healthcare (CHC) GBU (including the emerging markets) sales were €1.15 billion, down 5.2% as higher sales in Emerging Markets were offset by lower sales in the United States and Europe. Sales declined 12.8% in the United States due to Sanofi’s voluntary recall of its over-the-counter acid reflux medicine Zantac, which is sold by the generic name of ranitidine by many other companies.
Meanwhile, non-core divestments and increased regulatory requirements, which resulted in product suspensions, also hurt the performance of the CHC segment.
Sanofi Pasteur (Vaccines) sales (including the emerging markets) rose 22% to €1.91 billion. U.S. sales of vaccines rose 33.1% in the quarter, reflecting the majority of U.S. influenza vaccine shipments in the fourth quarter. Sales also rose in Emerging Markets and Europe.
Costs Decline
Selling, general and administrative expenses declined 1.4% at CER in the quarter, reflecting cost-control measures. Research and development expenses declined 0.7% at CER due to smart spending initiatives as well as portfolio prioritization.
2020 Guidance
Sanofi expects earnings to grow approximately 5% at CER in 2020. It now anticipates a positive currency impact of around 1% on earnings.
Our Take
For the second quarter in a row, Sanofi’s results were mixed as it beat estimates for earnings but missed the same for sales. Double-digit growth in Specialty Care and Vaccines was offset by persistent sluggishness in Diabetes and Cardiovascular franchises and a weak performance in the CHC unit in the quarter. Its 2020 earnings outlook looked encouraging. Shares were up 3.4% in pre-market trading on Thursday. Sanofi’s shares have outperformed the industry in the past year. It has risen 13.1% in the said time frame compared with the industry’s increase of 11.9%.
Sanofi’s Specialty Care segment is on a strong footing particularly with regular label expansion of Dupixent. The drug has, in a very short time, become the key top-line driver for Sanofi. Importantly, Sanofi is discontinuing all its research activities in diabetes and cardiovascular area and will prioritize key growth drivers – Dupixent and vaccines. However, weak performance of the Diabetes unit, generic competition for many drugs and slower-than-expected uptake of core products like Praluent are headwinds.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong
Sanofi (SNY - Free Report) reported fourth-quarter 2019 earnings of 74 cents per American depositary share, which beat the Zacks Consensus Estimate of 70 cents. Earnings increased 21.8% on a reported basis. At constant currency rates (CER), earnings rose 17.3% driven by higher revenues and lower costs.
Fourth-quarter net sales of the French pharma giant rose 6.8% on a reported basis to $10.66 billion (€9.6 billion). Exchange rate movements benefited sales by 2.1% driven by a strong dollar and Japanese yen. At CER, sales increased 4.7% year over year. Sales however missed the Zacks Consensus Estimate of $11.12 billion.
Sales rose 11.8% at CER in the United States and 1.8% in the Emerging Markets. Sales were flat in Europe at CER but rose 0.6% in the Rest of the World (Japan, South Korea, Canada, Australia, New Zealand and Puerto Rico).
All growth rates mentioned below are on a year-on-year basis and at CER.
Segmental Performance
Sanofi reports through five Global Business Units (GBUs) — Sanofi Genzyme (Specialty Care), Primary Care, China & Emerging Markets, Consumer Healthcare and Vaccines.
At its Capital Markets Day held in December 2019, Sanofi announced plans to restructure the company‘s operations under three GBUs – Specialty Care (immunology, rare diseases, rare blood disorders, neurology and oncology), Vaccines and General Medicines (diabetes, cardiovascular, and established products). The company’s Consumer Healthcare (CHC) will operate as a standalone business unit.
Pharmaceuticals sales (including the emerging markets) rose 2.4% in the fourth quarter to €6.55 billion driven by key eczema drug, Dupixent, which was partially offset by lower Diabetes and Established Rx products sales.
Sanofi Genzyme/Specialty Care GBU sales (excluding the emerging markets) increased 19.7% to €2.53 billion, driven by Dupixent.
In the immunology franchise, Dupixent generated sales of €668 million in the quarter, up 133.1%. Sales of the drug in the United States were €545 million, up 134.7% driven by continued growth in atopic dermatitis and rapid uptake in new asthma indication and launch in chronic rhinosinusitis with nasal polyposis in June 2019. Sales in Europe were €64 million, up 117.2%.
Kevzara recorded sales of €53 million in the quarter, up 64.5%. Sanofi markets Dupixent and Kevzara in partnership with Regeneron Pharmaceuticals (REGN - Free Report) .
Sales of rare disease drugs increased 0.8% to €661 million. Myozyme/Lumizyme rose 2.1% to €197 million, Fabrazyme sales were €186 million, up 0.6%. Cerezyme sales declined 6.3% to €121 million.
Oncology sales increased 12.6% to €333 million. Key cancer drug Jevtana’s sales were up 10.1% to €123 million supported by higher sales in the United States.
Sales of multiple sclerosis drugs declined 3.8% to €517 million. Aubagio sales increased 3.9% to €465 million while sales of Lemtrada fell 42.5% to €52 million.
Rare blood disorders franchise, added to Sanofi’s portfolio with the acquisition of Bioverativ in 2018, fetched sales of €293 million, down 2.4% year over year. New drug Cablivi (caplacizumab) generated sales of €16 million in the quarter, lower than €20 million in the previous quarter, primarily due to price adjustments in Europe and increased assistance program participation in the United States. Sales of another drug in the franchise, Eloctate declined 14.9% in the quarter due to the ongoing competitive pressure in the United States.
Primary Care GBU comprises the Diabetes and Cardiovascular and the Established Rx Products segments. Sales in the Primary Care GBU declined 8.7% to €2.33 billion hurt by lower sales in Diabetes and Established Products.
The Diabetes franchise (excluding the emerging markets) declined 15.5% to €861 million due to lower sales of key drugs — Lantus and Toujeo.
Sales of diabetes drugs in the United States declined 20.5% to €454 million due to pricing pressure and loss of Part D business. In Europe, it dropped 4.4% and in rest of the world, it declined 21.8%.
Lantus sales decreased 23.9% to €485 million in the quarter. Lantus sales plunged 26.9% in the United States due to lower average net price and change in coverage with respect to Sanofi’s Part D business. In Europe, sales decreased 13.1% due to biosimilar competition and patient switching to Toujeo.
Toujeo generated sales of €186 million in the reported quarter, up 1.7%. Sales rose 14.3% in Europe while it declined 7.4% in the United States.
Admelog, a rapid-acting insulin, similar to Lilly’s (LLY - Free Report) Humalog, achieved sales worth €56, down 1.8% year over year.
In the cardiovascular franchise, Sanofi’s anti PCSK9 therapy, Praluent, garnered worldwide sales of €68 million in the reported quarter, down 14.1%. Sales in the United States declined due to significantly higher rebates offered by Sanofi and partner Regeneron to payers to improve access to the drug. Amgen (AMGN - Free Report) is also facing similar issues with its PCSK9 inhibitor, Repatha. Sales of the other drug, Multaq, in this franchise rose 1.1% to €97 million.
Sales of Established Rx Products came in at €1.3 billion, down 4% mainly due to lower sales of Plavix and Aprovel in China due to anticipated price and inventory adjustments in the channel. Meanwhile, lower sales of Lovenox in Europe and generic competition for Renvela/Renagel in the United Sales also hurt segment sales.
China and Emerging Markets GBU declined 1.9% to €1.7 billion.
Consumer Healthcare (CHC) GBU (including the emerging markets) sales were €1.15 billion, down 5.2% as higher sales in Emerging Markets were offset by lower sales in the United States and Europe. Sales declined 12.8% in the United States due to Sanofi’s voluntary recall of its over-the-counter acid reflux medicine Zantac, which is sold by the generic name of ranitidine by many other companies.
Meanwhile, non-core divestments and increased regulatory requirements, which resulted in product suspensions, also hurt the performance of the CHC segment.
Sanofi Pasteur (Vaccines) sales (including the emerging markets) rose 22% to €1.91 billion. U.S. sales of vaccines rose 33.1% in the quarter, reflecting the majority of U.S. influenza vaccine shipments in the fourth quarter. Sales also rose in Emerging Markets and Europe.
Costs Decline
Selling, general and administrative expenses declined 1.4% at CER in the quarter, reflecting cost-control measures. Research and development expenses declined 0.7% at CER due to smart spending initiatives as well as portfolio prioritization.
2020 Guidance
Sanofi expects earnings to grow approximately 5% at CER in 2020. It now anticipates a positive currency impact of around 1% on earnings.
Our Take
For the second quarter in a row, Sanofi’s results were mixed as it beat estimates for earnings but missed the same for sales. Double-digit growth in Specialty Care and Vaccines was offset by persistent sluggishness in Diabetes and Cardiovascular franchises and a weak performance in the CHC unit in the quarter. Its 2020 earnings outlook looked encouraging. Shares were up 3.4% in pre-market trading on Thursday. Sanofi’s shares have outperformed the industry in the past year. It has risen 13.1% in the said time frame compared with the industry’s increase of 11.9%.
Sanofi’s Specialty Care segment is on a strong footing particularly with regular label expansion of Dupixent. The drug has, in a very short time, become the key top-line driver for Sanofi. Importantly, Sanofi is discontinuing all its research activities in diabetes and cardiovascular area and will prioritize key growth drivers – Dupixent and vaccines. However, weak performance of the Diabetes unit, generic competition for many drugs and slower-than-expected uptake of core products like Praluent are headwinds.
Zacks Rank
Sanofi currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Sanofi Price, Consensus and EPS Surprise
Sanofi price-consensus-eps-surprise-chart | Sanofi Quote
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>